All of the articles on this topic suggest that, and Hahn has shown himself to be a tool.
https://www.pmlive.com/pharma_news/covid-19_vaccine_approval_unlikely_before_november,_says_us_nih_director_1346891
US National Institutes of Health (NIH) Director Francis Collins said regulatory approval for any potential COVID-19 vaccine included in the government’s Operation Warp Speed is unlikely to occur before November.
In an interview with reporters, Collins said even the most promising coronavirus vaccine candidates will not win approval any earlier than November or December, and
added that testing a vaccine in at least 10,000 people could potentially provide enough data to support wide-scale distribution.
“I would not expect, on the basis of what we know scientifically, that we would be at the point where the US Food and Drug Administration could make such a judgment until considerably later than 1 October,” said Collins, adding: “Maybe November or December would be my best bet.”
The Trump administration-backed Operation Warp Speed initiative aims to deliver 300 million doses of a COVID-19 vaccine to the American public by January 2021.
A host of vaccine candidates have already been selected to receive funding, in a bid to advance development and bolster manufacturing capabilities for their respective COVID-19 candidates. This includes potential vaccines from Johnson & Johnson, AstraZeneca/Oxford University, Pfizer/BioNTech, GlaxoSmithKline/Sanofi, Moderna and Novavax.
In the same call with reporters, Collins said he is confident that at least one of the several candidates funded by Operation Warp Speed will be shown to be safe and effective by the end of the year.
Last week, President Donald Trump
announced that it was possible a coronavirus vaccine would be available in the US before the start of the general election on 3 November. However, Collins dismissed concerns that Operation Warp Speed is advancing candidates too quickly without determining safety and efficacy first.
https://www.ft.com/content/b053f55b-2a8b-436c-8154-0e93dcdb3c1a {may be behind paywall}
http://archive.is/kdTbc {archived version}
The Trump administration is considering bypassing normal US regulatory standards to fast-track an experimental coronavirus vaccine from the UK for use in America ahead of the presidential election, according to three people briefed on the plan.
One option being explored to speed up the availability of a vaccine would involve the US Food and Drug Administration awarding “emergency use authorisation” (EUA) in October to a vaccine being developed in a partnership between AstraZeneca and Oxford university, based on the results from a relatively small UK study if it is successful, the people said.
The AstraZeneca study has enrolled 10,000 volunteers, whereas the US government’s scientific agencies have said that a vaccine would need to be studied in 30,000 people to pass the threshold for authorisation. AstraZeneca is also conducting a larger study with 30,000 volunteers, although the results from that will come after the smaller trial.
Making a vaccine available before the election could allow US president Donald Trump to claim he has turned the tide on a virus that has killed more than 170,000 Americans following widespread criticism of his handling of the pandemic. In his convention speech on Thursday night, Joe Biden, Mr Trump’s Democratic opponent, said that the US response to the virus was the “worst performance of any nation”.
= new reply since forum marked as read
